Hostname: page-component-745bb68f8f-kw2vx Total loading time: 0 Render date: 2025-01-30T05:37:59.712Z Has data issue: false hasContentIssue false
  • English
  • Français

Parkinsonism Induced By 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine (MPTP): Implications for Treatment and the Pathogenesis of Parkinson’s Disease

Published online by Cambridge University Press:  18 September 2015

J. William Langston  and
Phillip Ballard
Phillip Ballard
Affiliation:
Department of Neurology, Santaclara Valley Medical Center, Institute for Medical Research, San Jose, California and the Stanford University School of Medicine, Stanford, California
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Our experience in treating 7 patients with moderate to severe parkinsonism induced by l-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) is reviewed. Virtually all of the problems typically encountered with dopamine precursor and agonist therapy in treating Parkinson’s disease have been observed during a one and one half year follow-up period, including “end-of-dose” deterioration (or “wearing off’), “peak-dose” dyskinesias, “on-off” phenomena, and psychiatric complications. These have occurred much earlier than is typically seen when treating the idiopathic disease. This rapid evolution of therapeutic side-effects favors the view that at least some of the complications of dopamine precursor therapy may be related to severity of disease rather than the length of levodopa therapy. Finally, we suggest that the occurrence of this full array of therapeutic complications in patients with MPTP-induced parkinsonism furthers the analogy between this syndrome and Parkinson’s disease.

Type
4. Toxic Environmental Factors Causing Parkinsonism
Information
Canadian Journal of Neurological Sciences , Volume 11 , Issue S1: Current Concepts and Controversies in Parkinson’s Disease , February 1984 , pp. 160 - 165
Copyright
Copyright © Canadian Neurological Sciences Federation 1984

References

Barbeau, A (1980) High-level levodopa therapy in severely akinetic parkinsonian patients: Twelve years later. In: Parkinson’s Disease: Current Progress, Problems, and Management, Rinne, UK, Klingler, M, Stamm, G (eds). Elsivier/North Holland Biomedical Press, Amsterdam, pp 229–239.Google Scholar
Burns, RS, Chiueh, CC, Markey, SP, Ebert, MH, Jacobowitz, DM, Kopin, IJ (1983) A primate model of parkinsoniam: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine. Proc Natl Acad Sci 80: 4546–4550.CrossRefGoogle Scholar
David, GC, Williams, AC, Markey, SP, Ebert, MH, Caine, ED, Reichert, CM, Kopin, IJ (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1: 249–254.Google Scholar
Ezrin-Waters, C, Seeman, P (1978) L-Dopa reversal of hyperdopaminergic behavior. Life Sci 22: 1027–1032.CrossRefGoogle Scholar
Fahn, S (1982) Fluctuations of disability in Parkinson’s Disease: Pathophysiology. In: Movement Disorders, Marsden, CD, Fahn, S (eds). Butterworth Scientific, London, pp 123–145.Google Scholar
Forno, LS (1982) Pathology of Parkinson’s Disease, In: Movement Disorders, Marsden, CD, Fahn, S (eds). Butterworth Scientific, London, pp 25–40.Google Scholar
Friedhoff, AJ, Bonnett, K, Rosengartèn, H (1977) Reversal of two manifestations of dopamine receptor supersensitivity by administration of L-dopa. Res Commun Chem Pathol Parmacol 16: 411–423.Google ScholarPubMed
Granerus, AK (1978) Factors influencing the occurrence of “on-off” symptoms during long-term treatment with L-dopa. Acta Med Scand 203: 75–78.CrossRefGoogle ScholarPubMed
Hoehn, MM, Yahr, MD (1967) Parkinsonism: Onset, progression and mortality. Neurology 17: 427–442.CrossRefGoogle ScholarPubMed
Klawans, HL, Goetz, CNausidea, PA, Weiner, WJ (1977) Levodopa-induced dopamine receptorhypersensitivity. Ann Neurol 2:125–129.CrossRefGoogle Scholar
Lang, AE, Meadows, JC, Parkes, JO, Marsden, CD (1982) Early onset of the “on-off’ phenomenon in children with symptomatic Parkinsonism. J Neurol, Neurosurg and Psychiat 45: 823–825.CrossRefGoogle ScholarPubMed
Langston, JW, Ballard, P, Tetrud, JW, Irwin, I (1983a) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980.CrossRefGoogle ScholarPubMed
Langston, JW, Forno, LS, Rebert, CS, Irwin, I (In press (b)) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Research.Google Scholar
Lesser, RP, Fahn, S, Snider, SR.Cote, LJ, Isgreen, WP, Barrett, RE (1979) Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29: 1253–1260.CrossRefGoogle ScholarPubMed
Marsden, CD, Parkes, JD (1976) “On-off’ effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 1:292–296.CrossRefGoogle ScholarPubMed
Mones, RJ, Elizan, TS, Siegel, GJ (1971) Analysis of L-dopa induced dyskinesias in 51 patients with Parkinsonism. J Neurol Neurosurg Psychiat 34: 668–673.CrossRefGoogle ScholarPubMed
Muenter, MD, Tyce, GM (1971) L-dopa therapy of Parkinson’s disease: Plasma L-dopa concentrations, therapeutic response, and side effects. Mayo Clinic Proceedings 46: 231–239.Google ScholarPubMed
Shoulson, I, Glaubiger, GA, Chase, TN (1975) On-off response: Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25: 1144–1148.CrossRefGoogle ScholarPubMed
Sweet, RD, McDowell, FH (1975) Five years’ treatment of Parkinson’s disease with levodopa: Therapeutic results and survival of 100 patients. Ann Intern Med 83: 456–463.CrossRefGoogle ScholarPubMed